• List
• Write
• 게시판 리스트 옵션
  • Modity
  • Delete

Immunoassay Systems and Kits Market: Automation, Precision, and the Future of Diagnostic Testing

Immunoassay systems and kits have become an essential part of modern laboratory diagnostics, supporting the detection and measurement of biomarkers associated with infectious diseases, cancer, cardiovascular conditions, hormonal disorders, and other health conditions. As healthcare providers increasingly prioritize faster, accurate, and scalable testing, demand for automated immunoassay platforms and advanced reagent kits continues to expand. According to Emergen Research, the global Immunoassay Systems and Kits Market was valued at USD 28.64 billion in 2025 and is projected to reach USD 49.19 billion by 2035, registering a compound annual growth rate (CAGR) of 5.6% from 2026 to 2035.

Automation is one of the most important factors reshaping the immunoassay market. Traditional enzyme immunoassays can require multiple manual steps, including pipetting, incubation, washing, and result interpretation. These processes can increase workload and introduce variations between operators. Automated platforms address many of these challenges by standardizing sample processing and measurement, enabling laboratories to handle larger testing volumes while maintaining consistent workflows. The growing consolidation of hospital and reference-laboratory testing onto high-throughput platforms is also encouraging laboratories to adopt systems capable of processing large numbers of samples efficiently.

Get a Sample: https://www.emergenresearch.com/request-free-sample/220419 

Chemiluminescence immunoassay technology is particularly important in this transition. The technology uses a light-producing reaction to detect target analytes and is widely used in automated laboratory systems. In 2025, chemiluminescence immunoassay accounted for the largest share of the market by technology, representing 58.3% of revenue. Its combination of sensitivity, automation, throughput, and compatibility with broad diagnostic menus makes it an important technology for laboratories seeking reliable high-volume testing.

The product landscape is similarly centered on consumables. Reagents and kits accounted for the largest product-type share in 2025, at 71.8%. This reflects the recurring nature of diagnostic testing. Once a laboratory installs an immunoassay analyser, it continually requires compatible reagents, calibrators, controls, and other consumables to conduct tests. As installed instrument bases expand and diagnostic menus become broader, recurring kit demand can create an important source of revenue for manufacturers.

Applications across infectious disease, oncology, endocrinology, metabolism, and cardiology are also supporting market expansion. Infectious disease represented the largest application segment in 2025, accounting for 26.7% of market revenue. Immunoassays are widely used for detecting antibodies, antigens, and other biological markers associated with infections. At the same time, oncology and cardiology are generating demand for increasingly specialized biomarker testing, while endocrine and metabolic testing continues to support routine laboratory workloads.

The development of blood-based biomarkers is creating additional opportunities. This trend is particularly relevant as healthcare systems look for diagnostic approaches that can be performed with minimally invasive samples and integrated into existing laboratory workflows. Blood-based testing can improve accessibility for selected conditions and may help clinicians obtain quantitative information without relying exclusively on imaging or invasive sampling. As research identifies additional clinically useful biomarkers, immunoassay manufacturers can potentially expand the number of assays supported by established analyser platforms.

Tumor markers, cardiac troponin, natriuretic peptides, procalcitonin, thyroid markers, fertility-related hormones, and emerging neurological biomarkers can expand the testing menu available on existing laboratory platforms. This approach allows laboratories to add new diagnostic capabilities without necessarily replacing their installed analysers. It can also improve utilization of existing laboratory infrastructure and support more comprehensive testing within established workflows while helping laboratories meet changing clinical demand.

North America currently represents the largest regional market. The region accounted for 36.9% of global revenue in 2025, supported by an established healthcare infrastructure, extensive laboratory networks, advanced diagnostic technologies, and strong adoption of automated testing systems. The United States led the North American market during the year. Meanwhile, Asia Pacific is projected to record the fastest CAGR during the forecast period, reflecting increasing healthcare investment, expanding diagnostic capacity, and rising demand for advanced laboratory testing.

Despite these opportunities, the market faces several restraints. Healthcare pricing reforms and volume-based procurement programs in China are putting pressure on diagnostic pricing. Manufacturers are also dealing with changes in testing volumes following the decline of pandemic-related COVID-19 testing. Competitive pricing strategies can further affect revenue growth, particularly when vendors seek to protect installed customer bases. In addition, closed reagent systems can create long-term dependence on specific suppliers, potentially limiting flexibility for laboratories and making market entry more challenging for newer assay developers.

Regulatory requirements also remain an important consideration. Immunoassay analysers and kits are regulated as in vitro diagnostic medical devices, and manufacturers must meet applicable requirements for safety, performance, quality, and intended use. In the United States, the Food and Drug Administration regulates commercial immunoassay systems and kits, while laboratory-developed tests remain subject to the applicable Clinical Laboratory Improvement Amendments framework. In Europe, the In Vitro Diagnostic Medical Devices Regulation has introduced risk-based requirements and transitional arrangements for legacy devices. These regulatory frameworks can influence product development timelines, certification requirements, and market access strategies.

Read More: https://www.emergenresearch.com/industry-report/immunoassay-systems-and-kits-market 

Competition is therefore increasingly focused on more than instrument performance alone. Manufacturers are seeking to strengthen their positions through expanded test menus, automation, connectivity, reagent availability, and workflow integration. Companies including Roche, Abbott, Siemens Healthineers, Danaher through Beckman Coulter, bioMérieux, DiaSorin, QuidelOrtho, Mindray, and Fujirebio participate across different parts of the immunoassay value chain.

Overall, the Immunoassay Systems and Kits Market is moving toward greater automation, broader diagnostic menus, and more efficient laboratory workflows. The combination of recurring reagent demand, high-throughput platforms, emerging blood-based biomarkers, and expanding diagnostic needs is expected to support continued market development. With the global market projected to rise from USD 28.64 billion in 2025 to USD 49.19 billion by 2035, immunoassay technologies are positioned to remain an important component of clinical diagnostics and laboratory medicine over the coming decade.